IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report)'s share price traded down 1.6% during trading on Monday . The stock traded as low as $1.19 and last traded at $1.22. 205,121 shares were traded during trading, a decline of 52% from the average session volume of 430,251 shares. The stock had previously closed at $1.24.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on ICCM shares. HC Wainwright restated a "buy" rating and issued a $2.50 price target on shares of IceCure Medical in a research report on Wednesday, November 27th. Alliance Global Partners upgraded IceCure Medical to a "strong-buy" rating in a report on Friday, November 1st.
Check Out Our Latest Report on ICCM
IceCure Medical Stock Down 0.4 %
The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The firm's fifty day moving average price is $1.08 and its 200-day moving average price is $0.80. The company has a market cap of $69.10 million, a price-to-earnings ratio of -4.31 and a beta of 0.37.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. Sell-side analysts predict that IceCure Medical Ltd will post -0.28 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 66,400 shares of the company's stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is owned by institutional investors.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Stories
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
